Coinfection in hepatitis;Koinfektionen bei hepatitis

Zeitschrift fur Gastroenterologie

Volumn 42, Issue 8, 2004, Pages 724-730

  Haussinger D ^a,b   Erhardt, A ^a   Oette, M ^a  

^a Hepatologie Infektiologie H   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; DIDANOSINE; FAMCICLOVIR; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; RIBAVIRIN; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

DELTA AGENT HEPATITIS; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW; SUPERINFECTION;

CARCINOMA, HEPATOCELLULAR; CONSENSUS; DISEASE PROGRESSION; GERMANY; HEPATITIS; HEPATITIS B, CHRONIC; HEPATITIS C; HEPATITIS C, CHRONIC; HEPATITIS, VIRAL, HUMAN; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; PATIENT CARE MANAGEMENT; PRACTICE GUIDELINES;

EID: 4444322935     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-813446     Document Type: Review

References (110)

1. Hadziyannis SJ. Review: hepatitis delta. J Gastroenterol Hepatol 1997; 12 (4): 289-298 (III)
2. Moller B et al. Z Gastroenterol 1988; 26 (6): 314-321 (III)
3. Roggendorf M et al. Epidemiological studies on the prevalence of hepatitis Delta virus infections in the Federal Republic of Germany. J Hepatol 1986; 2 (2): 230-236 (III)
4. Erhardt A et al. Socioepidemiological data on hepatitis delta in a german university clinic - increase of patients from Eastern Europe and the former Sovjet Union. Z Gastroenterol 2003 (in press) (III)
5. Hadler SC et al. Delta virus infection and severe hepatitis. An epidemic in the Yucpa Indians of Venezuela. Ann Intern Med 1984; 100 (3): 339-344 (III)
6. Caredda F et al. Hepatitis B virus-associated coinfection and superinfection with delta agent: indistinguishable disease with different outcome. J Infect Dis 1985; 151 (5): 925-928 (III)
7. Smedile A et al. Influence of delta infection on severity of hepatitis B. Lancet 1982; 2 (8305): 945-947 (III)
8. Govindarajan S et al. Fulminant B viral hepatitis: role of delta agent. Gastroenterology 1984; 86 (6): 1417-1420 (III)
9. Farci P et al. Delta hepatitis in inapparent carriers of hepatitis B surface antigen. A disease simulating acute hepatitis B progressive to chronicity. Gastroenterology 1983; 85 (3): 669-673 (III)
10. Hadler SC et al. Epidemiology and long-term consequences of hepatitis delta virus infection in the Yucpa Indians of Venezuela. Am J Epidemiol 1992; 136 (12): 1507-1516 (II a)
11. Huo TI et al. Comparison of clinico-pathological features in hepatitis B virus-associated hepatocellular carcinoma with or without hepatitis D virus superinfection. J Hepatol 1996; 25 (4): 439-444 (III)
12. Rizzetto M et al. Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. Ann Intern Med 1983; 98 (4): 437-441 (III)
13. Fattovich G et al. Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. J Infect Dis 1987; 155 (5): 931-935 (III)
14. Fattovich G et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut 2000; 46 (3): 420-426 (III)
15. Saracco G et al. Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta virus infection. J Hepatol 1987; 5 (3): 274-281 (III)
16. Verme G et al. Role of hepatitis delta virus infection in hepatocellular carcinoma. Dig Dis Sci 1991; 36 (8): 1134-1136 (III)
17. Rosina F et al. A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study. Hepatology 1991; 13 (6): 1052-1056 (I b)
18. Madejon A et al. Treatment of chronic hepatitis D virus infection with low and high doses of interferon-alpha 2a: utility of polymerase chain reaction in monitoring antiviral response. Hepatology 1994; 19 (6): 1331-1336 (I b)
19. Rosina F, Rizzetto M. Treatment of chronic type D (delta) hepatitis with alpha Interferon. Semin Liver Dis 1989; 9 (4): 264-266 (I b)
20. Farci P et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994; 330 (2): 88-94 (I b)
21. Gaudin JL, Trepo C. Therapy of chronic delta hepatitis with alpha- and beta-interferon. Prog Clin Biol Res 1993; 382: 345-352 (I b)
22. Di Marco V et al. Long-term interferon-alpha treatment of children with chronic hepatitis delta: a multicentre study. J Viral Hepat 1996; 3 (3): 123-128 (I b)
23. Lau DT et al. Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy. Gastroenterology 1999; 117 (5): 1229-1233 (IV)
24. Lau DT et al. Lamivudine for chronic delta hepatitis. Hepatology 1999; 30 (2): 546-549 (II b)
25. Yurdaydin C et al. Famciclovir treatment of chronic delta hepatitis. J Hepatol 2002; 37 (2): 266-271 (II b)
26. Wolters LM et al. Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus. J Viral Hepat 2000; 7 (6): 428-434 (II b)
27. Garripoli A et al. Ribavirin treatment for chronic hepatitis D: a pilot study. Liver 1994; 14 (3): 154-157 (II b)
28. Mason WS, Taylor JM. Liver transplantation: a model for the transmission of hepatitis delta virus. Gastroenterology 1991; 101 (6): 1741-1743 (III)
29. Samuel D et al. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. Hepatology 1995; 21 (2): 333-339 (III)
30. Rizzetto M et al. Liver transplantation in hepatitis delta virus disease. Lancet 1987; 2 (8557): 469-471 (III)
31. Lucey MR et al. Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. Gut 1992; 33 (10): 1390-1396 (III)
32. Liaw YF. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology 1995; 22 (4 Pt 1): 1101-1108 (III)
33. Tsai SL et al. Cellular immune responses in patients with dual infection of hepatitis B and C viruses: dominant role of hepatitis C virus. Hepatology 1995; 21 (4): 908-912 (II b)
34. Ilan Y et al. Chronic hepatitis C virus infection with exposure to hepatitis B virus. Isr J Med Sci 1994; 30 (4): 259-63 (III)
35. Mohamed Ael S, al Karawi MA, Mesa GA. Dual infection with hepatitis C and B viruses: clinical and histological study in Saudi patients. Hepatogastroenterology 1997; 44 (17): 1404-1406 (III)
36. Zarski JP et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998; 28 (1): 27-33 (III)
37. Chen YC et al. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002; 123 (4): 1084-1089 (III)
38. Kew MC et al. The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African blacks. Gastroenterology 1997; 112 (1): 184-187 (III)
39. Chuang WL et al. The role of hepatitis B and C viruses in hepatocellular carcinoma in a hepatitis B endemic area. A case-control study. Cancer 1992; 69 (8): 2052-2054 (III)
40. Kaklamani E et al. Hepatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma. Jama 1991; 265 (15): 1974-1976 (III)
41. Kubo S et al. Clinical significance of prior hepatitis B virus infection in patients with hepatitis C virus-related hepatocellular carcinoma. Cancer 1999; 86 (5): 793-798 (III)
42. Zignego AL et al. Impaired response to alpha Interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection. Arch Virol 1997; 142 (3): 535-544 (II a)
43. Fukuda R et al. Effectiveness of interferon-alpha therapy in chronic hepatitis C is associated with the amount of interferon-alpha receptor mRNA in the liver. J Hepatol 1997; 26 (3): 455-461 (II a)
44. Weltman MD et al. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat 1995; 2 (1): 39-45 (II b)
45. Villa E et al. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. Am J Gastroenterol 2001; 96 (10): 2973-2977 (II a)
46. Liaw YF et al. Clinical and virological course of chronic hepatitis B virus infection with hepatitis C and D virus markers. Am J Gastroenterol 1998; 93 (3): 354-359 (III)
47. Pontisso P et al. Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology 1993; 105 (5): 1529-1533 (III)
48. Jardi R et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology 2001; 34 (2): 404-410 (III)
49. Mathurin P et al. Replication status and histological features of patients with triple (B, C, D) and dual (B, C) hepatic infections. J Viral Hepat 2000; 7 (1): 15-22 (III)
50. Sagnelli E et al. Virologie and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology 2000; 32 (5): 1106-1110 (III)
51. Thio CL et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360 (9349): 1921-1926 (III)
52. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991; 163 (5): 1138-1140 (III)
53. Hadler SC et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991; 163 (3): 454-459 (III)
54. Colin JF et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29 (4): 1306-1310 (III)
55. Gilson RJ et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. Aids 1997; 11 (5): 597-606 (III)
56. Puoti M et al. Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. AIDS Rev 2002; 4 (1): 27-35 (I b)
57. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337 (24): 1733-1745 (II b)
58. Sinicco A et al. Coinfection and superinfection of hepatitis B virus in patients infected with human immunodeficiency virus: no evidence of faster progression to AIDS. Scand J Infect Dis 1997; 29 (2): 111-115 (III)
59. Wit FW et al. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186 (1): 23-31 (III)
60. Ellozy S et al. Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature. Am Surg 2001; 67 (7): 680-683 (IV)
61. Martinez E et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. Aids 2001; 15 (10): 1261-1268 (III)
62. Nunez M et al. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27 (5): 426-431 (III)
63. den Brinker M et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. Aids 2000; 14 (18): 2895-2902 (III)
64. Gisolf EH et al. Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group. Clin Infect Dis 2000; 31 (5): 1234-1239 (II b)
65. Sulkowski MS et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. Jama 2000; 283 (1): 74-80 (III)
66. Ockenga J et al. Wien Med Wochenschr 1997; 147 (19-20): 439-442 (III)
67. Saves M et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe d'Epidemiologie Clinique de Sida en Aquitaine (GECSA). Aids 1999; 13 (17): F115-F121 (III)
68. Buti M et al. Chronic delta hepatitis: is the prognosis worse when associated with hepatitis C virus and human immunodeficiency virus infections? J Med Virol 1996; 49 (1): 66-69 (III)
69. Pol S et al. Influence of human immunodeficiency virus infection on hepatitis delta virus superinfection in chronic HBsAg carriers. J Viral Hepat 1994; 1 (2): 131-137 (III)
70. McDonald JA et al. Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant alpha-interferon. Hepatology 1987; 7 (4): 719-723 (I b)
71. Hopf U et al. Z Gastroenterol 1997; 35 (11): 971-986 (IV)
72. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGuidelines Group for HIV resistance. Aids 2001; 15 (3): 309-320 (IV)
73. Carton JA et al. Lamivudine for chronic hepatitis B and HIV co-infection. Aids 1999; 13 (8): 1002-1003 (III)
74. Benhamou Y et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30 (5): 1302-1306 (II b)
75. Hoff J et al. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. Clin Infect Dis 2001; 32 (6): 963-969 (III)
76. Dore GJ et al. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis 1999; 180 (3): 607-613 (III)
77. Pillay D et al. Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. CAESAR co-ordinating committee. Aids 2000; 14 (9): 1111-1116 (III)
78. Bruno R et al. YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient. Gastroenterology 2001; 121 (4): 1027-1028 (IV)
79. Petry W, Adams O, Häussinger D. Fatal hepatitis B reinfection after orthotopic liver transplantation in an HBsAg negative patient following withdrawal of lamivudine. J Hepatol 2000; 33 (3): 514-515 (IV)
80. Bessesen M et al. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999; 28 (5): 1032-1035 (III)
81. Ristig MB et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis 2002; 186 (12): 1844-1847 (II b)
82. Benhamou Y et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358 (9283): 718-723 (II b)
83. Nelson M et al. An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals. Aids 2003; 17 (1): F7-F10 (II b)
84. Wong DK et al. Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population. Gastroenterology 1995; 108 (1): 165-171 (I b)
85. Brook MG et al. Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response. Gut 1989; 30 (8): 1116-1122 (I b)
86. DiMartino V et al. Serum alanine transaminase level is a good predictor of response to interferon alfa therapy for chronic hepatitis B in human immunodeficiency virus-infected patients. Hepatology 2000; 31 (4): 1030-1031
87. Di Martino V et al. Long-term effects of interferon-alpha in five HIV-positive patients with chronic hepatitis B. J Viral Hepat 1996; 3 (5): 253-260 (III)
88. Marcellin P et al. Recombinant alpha interferon for chronic hepatitis B in anti-HIV positive patients receiving zidovudine. Gut 1993; 34 (2 Suppl): S106 (II b)
89. Visco G et al. Zidovudine plus interferon alfa-2b treatment in patients with HIV and chronic active viral hepatitis. Gut 1993; 34 (2 Suppl): S107-S108 (II b)
90. Zylberberg H et al. Alpha-interferon for chronic active hepatitis B in human immunodeficiency virus-infected patients. Gastroenterol Clin Biol 1996; 20 (11): 968-971 (II b)
91. Wong DK et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119 (4): 312-323 (I a)
92. Soriano V et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. Aids 2002; 16 (6): 813-828 (I b)
93. Thomas DL. Hepatitis C and human immunodeficiency virus infection. Hepatology 2002; 36 (5 Suppl 1): S201-S209 (I b)
94. Di Martino V et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 2001; 34 (6): 1193-1199 (III)
95. Garcia-Samaniego J et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001; 96 (1): 179-183 (III)
96. Graham CS et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33 (4): 562-569 (I a)
97. Monga HK et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33 (2): 240-247 (II b)
98. Benhamou Y et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30 (4): 1054-1058 (II a)
99. Darby SC et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 1997: 350 (9089): 1425-1431 (III)
100. Rockstroh JK et al. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol 1996; 91 (12): 2563-2568 (III)
101. De Luca A et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med 2002; 162 (18): 2125-2132 (III)
102. Greub G et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356 (9244): 1800-1805 (III)
103. Piroth L et al. Hepatitis C virus co-infection is a negative prognostic factor for clinical evolution in human immunodeficiency virus-positive patients. J Viral Hepat 2000; 7 (4): 302-308 (III)
104. Sulkowski MS et al. Hepatitis C and progression of HIV disease. Jama 2002; 288 (2): 199-206 (III)
105. Cacoub P et al. Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997. Clin Infect Dis 2001; 32 (8): 1207-1214 (III)
106. George SL et al. Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests. J Acquir Immune Defic Syndr 2002; 31 (2): 154-162 (II b)
107. Bruno R et al. HCV chronic hepatitis in patients with HIV: clinical management issues. Am J Gastroenterol 2002; 97 (7): 1598-1606 (IV)
108. Di Martino V et al. HIV coinfection does not compromise liver histological response to interferon therapy in patients with chronic hepatitis C. Aids 2002; 16 (3): 441-445 (III)
109. Benhamou Y et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34 (2): 283-287 (II b)
110. Pol S, Vallet-Pichard A, Fontaine H. Hepatitis C and human immune deficiency coinfection at the era of highly active antiretroviral therapy. J Viral Hepat 2002; 9 (1): 1-8 (I b)